Table 3.

Results of the 5 multidimensional rating scales in the 3 treatment groups

	Baseline	6 months	12 months
MMSE
Donepezil	21.0±3.9	22.0±3.3*	21.3±4.3
Rivastigmine	21.0±3.5	22.6±3.2	21.1±3.6
Galantamine	20.8±3.7	21.6±3.3	18.9±3.7
ADAS-cog
Donepezil	18.2±8.1	16.6±5.9	16.5±8.0
Rivastigmine	16.9±4.6	17.2±3.8	16.5±4.1
Galantamine	15.5±5.4	16.6±6.9	18.6±7.2
TMT-Part A
Donepezil	107.5±35.9	86.5±34.4#	89.9±36.8
Rivastigmine	95.3±33.5	98.2±35.2	80.7±28.7
Galantamine	88.8±37.5	100.3±42.1	85.6±48.3
NPI
Donepezil	4.2±2.8	3.9±2.7	3.5±3.0
Rivastigmine	4.3±4.5	3.6±2.8	4.0±3.9
Galantamine	4.8±3.1	3.7±2.2	4.8±3.6
FAQ
Donepezil	13.4±8.1	14.4±6.3	12.6±7.3
Rivastigmine	12.9±6.2	13.6±4.5	13.4±4.2
Galantamine	12.3±6.7	13.4±6.3	15.9±7.6†

^#p < 0.05

^*p < 0.01, improvement versus baseline

^†p < 0.01, worsening versus baseline.